Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06059066 · ClinicalTrials.gov registry record · NA
Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction
A NA study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 78
- Enrollment target
NCT06059066 is a NA study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 78 participants.
The verdict
NCT06059066, a NA study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 78 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate and standardize the way providers perform OnabotulinumtoxinA (BTX-A) injections into the bladder for the diagnosis of neurogenic lower urinary tract dysfunction (NLUTD)/overactive bladder (OAB). NLUTD/OAB is a syndrome that affects many people, and includes urinary frequency, urinary urgency, urgency incontinence, and nocturia. This syndrome can be challenging to treat and often requires procedural management - including BTX-A injections into the bladder.
Interventions
- PROCEDURE Standard number of injection sites
- PROCEDURE Reduced number of injection sites
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2023-10-04 |
| Est. Completion | 2024-04-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06059066
The ClinicalTrials.gov registry entry for NCT06059066 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard number of injection sites is the first listed.
NCT06059066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06059066 about?
NCT06059066 is a clinical study titled "Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction". The purpose of this study is to evaluate and standardize the way providers perform OnabotulinumtoxinA (BTX-A) injections into the bladder for the diagnosis of neurogenic lower urinary tract dysfunction (NLUTD)/overactive bladder (OAB). NLUTD/OAB is a syndrome that affects many people, and includes u...
What is the current status of trial NCT06059066?
This trial is currently completed. It is a NA study. The enrollment target is 78 participants. The study started on 2023-10-04. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT06059066?
The interventions under investigation include: Standard number of injection sites (PROCEDURE), Reduced number of injection sites (PROCEDURE).
Who is sponsoring clinical trial NCT06059066?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.